Guided Therapeutics (GTHP) Interest Expenses (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Interest Expenses data on file, last reported at $184000.0 in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 607.69% year-over-year to $184000.0; the trailing twelve-month figure through Dec 2025 stood at $617000.0 (up 78.32% YoY), and the FY2025 full-year result was $17.4 million, down 0.93% from the prior year.
• Interest Expenses advanced to $184000.0 in Q4 2025, from $129000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $594000.0 in Q3 2021 to a low of -$493000.0 in Q4 2021.
• A 5-year average of $173900.0 and a median of $156000.0 in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses tumbled 159.61% in 2021 and soared 607.69% in 2025, its largest moves.
• Tracing GTHP's Interest Expenses over 5 years: stood at -$493000.0 in 2021, then surged by 200.0% to $493000.0 in 2022, then tumbled by 63.29% to $181000.0 in 2023, then sank by 85.64% to $26000.0 in 2024, then soared by 607.69% to $184000.0 in 2025.
• Business Quant data shows GTHP's Interest Expenses at $184000.0 in Q4 2025, $129000.0 in Q3 2025, and $157000.0 in Q2 2025.